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Abstract
Background: Little is known about the prevalence and incidence in low and middle-income countries (LMICs) of
secondary lymphedema due to cancer. The purpose of the study is to estimate the prevalence and incidence in
LMICs of secondary lymphedema related to cancer and/or its treatment(s) and identify risk factors.
Method: A systematic review and meta-analysis was conducted. Medline, EMBASE and CINAHL were searched in
June 2019 for peer-reviewed articles that assessed prevalence and/or incidence of cancer-related lymphedema in
LMICs. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Prevalence Studies.
Estimates of pooled prevalence and incidence estimates were calculated with 95% confidence intervals (CI), with
sub-group analyses grouping studies according to: country of origin, study design, risk of bias, setting, treatment,
and lymphedema site and measurement. Heterogeneity was measured using X2 and I2, with interpretation guided
by the Cochrane Handbook for Systematic Reviews.
Results: Of 8766 articles, 36 were included. Most reported on arm lymphedema secondary to breast cancer
treatment (n = 31), with the remainder reporting on leg lymphedema following gynecological cancer treatment
(n = 5). Arm lymphedema was mostly measured by arm circumference (n = 16/31 studies), and leg lymphedema
through self-report (n = 3/5 studies). Eight studies used more than one lymphedema measurement. Only two
studies that measured prevalence of leg lymphedema could be included in a meta-analysis (pooled prevalence =
10.0, 95% CI 7.0–13.0, I2 = 0%). The pooled prevalence of arm lymphedema was 27%, with considerable
heterogeneity (95% CI 20.0–34.0, I2 = 94.69%, n = 13 studies). The pooled incidence for arm lymphedema was 21%,
also with considerable heterogeneity (95% CI 15.0–26.0, I2 = 95.29%, n = 11 studies). There was evidence that higher
body mass index (> 25) was associated with increased risk of arm lymphedema (OR: 1.98, 95% CI 1.45–2.70, I2 =
84.0%, P < 0.0001, n = 4 studies).
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Conclusion: Better understanding the factors that contribute to variability in cancer-related arm lymphedema in
LMICs is an important first step to developing targeted interventions to improve quality of life. Standardising
measurement of lymphedema globally and better reporting would enable comparison within the context of
information about cancer treatments and lymphedema care.
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Background
Lymphedema is a distressing and often persistent condi-
tion that occurs when fluid accumulates in the extracel-
lular tissue spaces causing swelling, predominately in the
extremities [1]. Lymphedema is classified as congenital,
primary or secondary. Secondary lymphedema occurs as
a sequelae to another condition, such as the surgical
and/or radiation treatments of cancer [2, 3].
Lymphedema is characterised by heaviness and dis-
comfort, decreased range of motion, recurrent skin in-
fections, elephantiasis verruca nostra, recurrent skin
ulcers, cutaneous angiosarcoma, as well as psychological
effects including depression, anxiety, and negative body
image [4]. These effects impact adversely on quality of
life [5].
Systematic reviews of the estimates incidence and
prevalence of cancer-related lymphedema have focused
almost exclusively on high-income countries (HICs). A
2013 systematic review and meta-analysis found the inci-
dence of unilateral arm lymphedema post breast cancer
treatment ranged from 8.4 to 21.4% [6]. Another system-
atic review estimated the prevalence of secondary
lymphedema due to non-specific cancer in United King-
dom (UK) lymphedema specialist clinics (n = 11,555) to
be 2.05–3.99:1000 [7]. Risk factors for lymphedema
identified in the literature have included obesity at
the time of a cancer diagnosis, receipt of chemother-
apy, adjuvant radiation therapy, type of surgery, phy-
siotherapeutic modalities, and number of lymph nodes
removed [6, 8].
No review to date has reported on the pooled preva-
lence or incidence of lymphedema in LMICs and associ-
ated risk factors, making it difficult to advocate for and
plan appropriate services to manage this condition.
Aim
To estimate the prevalence and incidence in LMICs of
secondary lymphedema related to cancer and/or its
treatment(s) and identify risk factors.
Methods
A systematic review and meta-analysis was registered
with the International Prospective Register of Systematic
Reviews (PROSPERO) [CRD42019137641] [9]. This re-
view is reported in accordance with the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA) guidelines [10]. This paper reports on the
cancer-related lymphedema component of a larger re-
view across lymphedema from all causes.
Eligibility criteria
Primary studies in peer-reviewed journals of any design
that estimated prevalence or incidence of secondary
lymphedema in a sample from a LMIC, as defined by
The World Bank Group [11] criteria. Where studies
evaluated an intervention, only the baseline data were
included. Studies using various measures of secondary
lymphedema, including self-report and objective mea-
sures were included. Where studies were published in
languages other than English, native language speakers
were contacted to do the extraction according to the
predefined criteria. Editorials, comment papers, review
papers, case reports, and case series were excluded.
Information sources
Database searches were conducted of Medline, Excerpta
medica database (EMBASE) and Cumulative Index of
Nursing and Allied Health Literature (CINAHL). A hand
search of the reference lists of included studies was also
performed.
Search strategy
Databases were searched on seventh of June 2019 with-
out any limit on date or language. Subject headings and
keywords related to lymphedema and LMICs. The initial
search strategy was developed in Medline and adapted
for other bibliographic databases (refer to Table 1).
Study selection
The first author (E.T.) assessed titles and abstracts of all
citations retrieved by the search for relevance against the
inclusion criteria, obtaining full texts as required to
make a decision. 10% of articles were independently
screened by a second author (T.L., M.B. or J.P.), with
screening continued by E.T. alone after finding 100%
agreement.
Data extraction
Data were extracted by the first author (E.T.), with ran-
dom checks performed by a second (T.L.). Data items
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extracted included: year and country, setting, aims, study
design, sample size, sampling method, lymphedema site,
stage, severity and duration, the type of management
Table 1 Search strings for systematic review and meta-analysis
Medline
No. Searches
1. (((((((((Afghanistan* or Benin* or Burkina Faso* or Burundi* or
Central African
Republic* or Chad* or Comoros* or Congo* or Eritrea* or Ethiopia*
or Gambia*
or Guinea-Bissau* or Haiti* or Korea Republic* or Liberia* or
Madagascar* or
Malawi* or Mali* or Mozambique* or Nepal* or Niger* or Rwanda*
or Sierra
Leone* or Somalia* or South Sudan* or Syrian Arab Republic* or
Tajikistan* or
Tanzania* or Togo* or Uganda* or Yemen* or Zimbabwe* or
Angola* or
Bangladesh* or Bhutan* or Bolivia* or Cabo Verde* or Cambodia*
or Cameroon*
or Congo* or Ivory Coast* or Djibouti* or Egypt* or El Salvador* or
Georgia* or
Ghana* or Honduras* or India* or Indonesia* or Kenya* or Kiribati*
or Kosovo* or
Kyrgyz Republic* or Lao PDP* or Lesotho* or Mauritania* or
Micronesia* or
Moldova* or Mongolia* or Morocco* or Myanmar* or Nicaragua*
or Nigeria* or
Pakistan* or Papua New Guinea* or Philippines* or Sao Tome) and
Principe*) or
Solomon Islands* or Sri Lanka* or Sudan* or Swaziland* or Timor-
Leste* or
Tunisia* or Ukraine* or Uzbekistan* or Vanuatu* or Vietnam* or
West Bank) and
Gaza*) or Zambia* or Albania* or Algeria* or American Samoa* or
Armenia* or
Azerbaijan* or Belarus* or Belize* or Bosnia) and Herzegovina*) or
Botswana* or
Brazil* or Bulgaria* or China* or Colombia* or Costa Rica* or Cuba*
or
Dominica* or Dominican Republic* or Equatorial Guinea* or
Ecuador* or Fiji* or
Gabon* or Grenada* or Guatemala* or Guyana* or Iran* or Iraq* or
Jamaica* or
Jordan* or Kazakhstan* or Lebanon* or Libya* or Macedonia* or
Malaysia* or
Maldives* or Marshall Islands* or Mauritius* or Mexico* or
Montenegro* or
Namibia* or Nauru* or Paraguay* or Peru* or Romania* or Russian
Federation*
or Samoa* or Serbia* or South Africa* or Saint Lucia* or Saint
Vincent) and the
Grenadines*) or Suriname* or Thailand* or Tonga* or Turkey* or
Turkmenistan*
or Tuvalu* or Venezuela*).mp.
2. ((Developing or underdeveloped or under-developed or less-
developed or least-developed) adj world).mp.
3. (Asia* or Africa* or Caribbean* or central America* or south
America* or
Melanesia* or Micronesia* or Polynesia*).mp.
4. ((developing or underdeveloped or under-developed or less-
developed or least developed
or less-economically developed or less-affluent or least-affluent) adj
(country or countries or nation or nations or region or regions or
economy or
economies)).mp.
5. (Third-world* or third world* or 3rd-world*).mp.
6. Developing countries/ or exp. africa/ or exp. Caribbean region/ or
exp. central
America/ or latin America/ or exp. south america/ or asia/ or exp.





exp. asia, southeastern/ or exp. asia, western/ or exp. indian ocean
islands/ or
pacific islands/ or exp. melanesia/ or exp. micronesia/ or exp. west
indies/
7. or/1–6
8. edema.mp. or Edema/
9. oedema.mp.
10 Elephantiasis, Filarial/ or lymphoedema.mp. or Elephantiasis/
11. exp Lymphedema/
12. lymhoedema.mp.





17. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
18. 7 and 17
19 limit 18 to humans
20. (((((((((‘Andorra’ or ‘Antigua) and Barbuda’) or ‘Argentina’ or ‘Aruba’
or ‘Australia’ or
‘Austria’ or ‘Bahamas’ or ‘Bahrain’ or ‘Barbados’ or ‘Belgium’ or
‘Bermuda’ or
‘British virgin islands’ or ‘Brunei Darussalam’ or ‘Canada’ or ‘Cayman
Islands’ or
‘Channel Islands’ or ‘Chile’ or ‘Croatia’ or ‘Curacao’ or ‘Cyprus’ or
‘Czech Republic’ or
‘Denmark’ or ‘Estonia’ or ‘Faroe Islands’ or ‘Finland’ or ‘France’ or
‘French Polynesia’
or ‘Germany’ or ‘Gibraltar’ or ‘Greece’ or ‘Greenland’ or ‘Guam’ or
‘Hong Kong Sar’ or
‘China’ or ‘Hungary’ or ‘Iceland’ or ‘Ireland’ or ‘Isle of Man’ or ‘Israel’
or ‘Italy’ or
‘Japan’ or ‘Korea’ or ‘Kuwait’ or ‘Latvia’ or ‘Liechtenstein’ or
‘Lithuania’ or
‘Luxembourg’ or ‘Macao Sar’ or ‘Malta’ or ‘Monaco’ or ‘Netherlands’
or ‘New
Caledonia’ or ‘New Zealand’ or ‘Northern Mariana Islands’ or
‘Norway’ or ‘Oman’ or
‘Palau’ or ‘Panama’ or ‘Poland’ or ‘Portugal’ or ‘Puerto Rico’ or
‘Qatar’ or ‘San
Marino’ or ‘Saudi Arabia’ or ‘Seychelles’ or ‘Singapore’ or ‘Sint
Maarten’ or ‘Slovak
Republic’ or ‘Slovenia’ or ‘Spain’ or ‘Saint Kitts) and Nevis’) or ‘Saint
Martin’ or
‘Sweden’ or ‘Switzerland’ or ‘Taiwan’ or ‘Trinidad) and Tobago’) or
‘Turks) and Caicos
Islands’) or ‘United Arab Emirates’ or ‘United Kingdom’ or ‘United
States’ or
‘Uruguay’ or ‘Virgin Islands’).mp.
21. 19 not 20
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reported, and estimates of lymphedema prevalence or
incidence.
Risk of bias (quality) assessment
The first author (E.T.) independently assessed risk of
bias for each study using the Joanna Briggs Institute
Critical Appraisal Checklist for Prevalence Studies [12].
20% of articles were independently assessed by the sec-
ond author (T.L.), with the remaining risk of bias assess-
ment continued by E.T. alone after a 100% agreement.
Disagreements were resolved by discussion or, and when
necessary, a third person arbitrating. The tool consists of
9 items which assess the internal and external validity of
studies included in the quantitative analysis [12]. Studies
were classified into low or high risk of bias using a cut-
off of 70%.
Statistical analysis
Meta-analyses of incidence and prevalence data were
undertaken separately in accordance with the Cochrane
Handbook for Systematic Reviews, using a random ef-
fects models [13]. The summary measure was the preva-
lent or incident percentage of people with lymphedema,
with 95% confidence intervals. Following Ressing et al.
[14], we assumed that cohort studies yielded estimates of
incidence whereas cross-sectional studies yielded esti-
mates of prevalence. Heterogeneity between estimates
was measured using X2 and I2 statistics, using recom-
mended thresholds [15]. For studies that used multiple
lymphedema measurements, we prioritized the following
measures based on level of objectivity [16, 17]: 1) cir-
cumferential measurement [18]; 2) perimetry (assessing
difference in limb sizes, similar to the circumferential
measurement) [6]; 3) limb volume measurement; 4)
bioimpedence spectroscopy; or 5) self-report.
Analysis of subgroups or subsets
Subgroup analyses were conducted on an a priori basis for
studies classified according to whether or not estimation
of prevalence/incidence was a stated aim of the study, and
low risk of bias. Further subgroup analyses were con-
ducted post hoc to explore any significant heterogeneity
based on study characteristics such as country, setting,
sample size, site and measurement of lymphedema and
study design. Where studies were not considered suffi-
ciently similar to be included in a meta-analysis, synthesis
used a narrative approach based on the methods pub-
lished by the Lancaster University, UK [19].
Results
Of the 8766 articles that were retrieved, 1231 articles
were excluded due to duplication. The remaining 7535
articles were evaluated, and 7109 were excluded based
on their title and abstract. Next, 426 full-text articles
were assessed and 389 were excluded, leaving 36 articles
for inclusion reporting 36 studies (Refer to Fig. 1).
Characteristics of included studies
The majority of studies (n = 34) focused on women (n =
12,145), while two studies [20, 21] involved both men
and women. All studies were conducted between 2001
and 2019 and three studies [22–24] were reported in
non-English language publications (Refer to Table 2).
While the majority of studies were conducted in Brazil
(n = 12) and Turkey (n = 9), most other regions with
LMIC were represented, including: South America (n =
12) [5, 20, 24, 32–39, 49], Europe (n = 11) [21, 23, 25–31,
50, 51], Southern Asia (n = 6) [41–45, 52], West Africa
(n = 3) [22, 40, 53], Middle East (n = 3) [47, 48, 54] and
East Asia and Pacific (n = 1) [46].
Most studies were cross-sectional (n = 21), with a
smaller number of prospective cohort (n = 8), retrospect-
ive cohort (n = 3) and case-control studies (n = 4). The
majority of studies (n = 34) reported exclusively on either
arm (n = 30) or leg (n = 4) lymphedema, while two [20,
40] reported on both. One study reported on lymph-
edema of the chest and arm secondary to breast cancer
treatment [35]. This study was the only study to use bio-
electric impedance to diagnose lymphedema [35]. Other
methods used for measuring and defining lymphedema
included: tape measurement (n = 16) [21, 25, 27–30, 32,
37, 38, 41–43, 45, 47, 48, 54]; patient self-report (n = 8)
[22, 33, 39, 44, 46, 50, 52, 53]; water volumeter (n = 2)
[31, 36]; palpation and clinical diagnosis (n = 2) [40, 49];
and perometer (n = 1) [34].
Twenty-five studies reported lymphedema prevalence
and 11 studies reported incidence.
Of the three studies that explored the risk of developing
lymphedema associated with cancer staging both in the
leg and arm, two involved women with breast cancer [30,
41] and the other, women with vulvar cancer [49]. Four
studies reported on the risk of developing arm lymph-
edema associated with breast cancer treatment among
women who had sentinel lymph node biopsy [5, 21, 29,
37]. Variations in the timing or the onset of cancer related
lymphedema ranged from 3 months to over 5 years post
diagnosis and treatment. The type of management re-
ceived by women with cancer related lymphedema in-
cluded: lymphatic drainage [29], physiotherapeutic
modalities such as care for the affected limb, home exer-
cises and self-lymphatic drainage [24, 28, 39], hormonal
therapy [54] and neo-adjuvant therapy including radio-
therapy and chemotherapy [34, 38].
Synthesis
Arm lymphedema following breast cancer treatment
The majority of studies (n = 31) reported arm lymph-
edema secondary to breast cancer treatment. However,
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lymphedema was defined differently based on the
method of measurement used. Half of these studies (n =
16) used circumferential measurements [21, 25, 27–30,
32, 37, 38, 41–43, 45, 47, 48, 54]. The remainder either
used self-reports of swelling in the arms (n = 5) [33, 39,
44, 46, 52], volumetric measurement (n = 2) [31, 36],
perimetry (n = 1) [34] and/or bioimpedance spectrom-
etry (n = 1) [26]. Six studies used more than one method
of arm lymphedema diagnosis [5, 20, 23, 24, 36, 51].
Eleven studies (n = 11) compared circumferential
measurement in bilateral limbs using a range difference
of ≥2 cm as indicative of lymphedema. One study from
Brazil only used a difference of ≥1 cm circumferential
measurement in the presence of any other two lymph-
edema symptoms of heaviness, swelling, tightness or
firmness in the affected limb [5]. Another study [23]
which examined the upper extremity disorders among
breast cancer women undergoing surgery measured
lymphedema as circumferential measurement differ-
ence ≥ 1.5 cm in the affected limb. There was only one
large population study involving Turkish women with
breast cancer (n = 5064), which used a cut-off difference
of ≥5 cm in the affected limb as a diagnosis for lymph-
edema [28]. All Turkish studies (n = 7) measured arm
lymphedema by the circumferential method, while the
Brazilian (n = 3) [24, 33, 39] and Indian (n = 2) [44, 52]
studies used patients’ self-reports.
Studies which used the volumetric measurement
defined lymphedema to be a cut-off difference in volume
based on circumferential measurements of both limbs >
10% percent [31, 36]. Lymphedema was diagnosed as an
impedance ratio of greater than 10 in the affected limb
using the bioimpedance spectrometer [26].
Prevalence of arm lymphedema following breast
cancer treatment The most common method of arm
lymphedema measurement was arm circumference (n =
16), while several studies (n = 9) also used more than just
one lymphedema measurement. One study used lym-
phoscintigraphy as a technique in the measurement of
lymphedema among Brazilian post-breast cancer women
[37]. All studies included in this review reported preva-
lence of arm lymphedema secondary to breast cancer
treatment. Twenty-five studies reported prevalence esti-
mates [5, 22, 23, 25, 27, 31–40, 43, 45–51, 53, 54]. The
prevalence estimate among post breast cancer treated
women varied from 0.4% in Papua New Guinea [46] to
92.5% reported by a Brazilian study [31]. The lowest
Fig. 1 Flow diagram of study selection for inclusion in this review and meta-analysis
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estimate of 0.4% was reported by self-report of lymph-
edema [46]. Of the two studies that reported on sentinel
lymph node biopsy, the prevalence estimates were rela-
tively low compared with other studies; 4.4% (95% CI
1.0–15.0) [37] and 17.0% (95% CI 11.0–27.0) [5].
Using data abstracted from 13 studies the pooled esti-
mate for prevalence of breast cancer related lymph-
edema was 30% (95% CI 24–37). There was considerable
heterogeneity among studies (I2 = 91.66%, p = 0.001)
(refer to Fig. 2). Heterogeneity was not reduced in a sub-
group analysis of studies grouped by a single country,
Brazil (pooled prevalence = 31, 95% CI 19.0–43.0, I2 =
87.21%, n = 5 studies). Studies from the Middle East (i.e.
Iran [54], Jordan [48] and Turkey [23]) demonstrated
considerable heterogeneity (I2 = 94.69%, p = 0.001),
which increased to considerable heterogeneity when a
second Turkish study [25] was included (I2 = 99.67%,
p = 0.001). The pooled prevalence recorded by the two
Turkish studies was 37% (95% CI 32–42) among breast
cancer women receiving treatment in cancer units (refer
to Fig. 3).
Incidence of arm lymphedema following breast
cancer treatment Eleven [11] studies reported incidence
of unilateral arm lymphedema [20, 21, 24, 26, 28–30, 41,
42, 44, 52], while one study reported lymphedema of
both arm and leg [20]. The follow up periods varied
among studies from 6months to over 5 years post- can-
cer treatment.
The lowest incidence was 5.9% after breast cancer
treatment in Romania [21] with a mean follow up period
of 24 months, who received sentinel lymph node biopsy.
The highest incidence was 56.7% recorded in an Indian
study with 6-month follow up after modified radical
mastectomy treatment for breast cancer patients [44].
Breast cancer related lymphedema incidence in Turkey
ranged from 7.2% recorded within a population sample
with a median follow up of 64 months [29] to 28% in a
population sample with a median follow up of 30
months after breast cancer treatment [30]. The inci-
dence of arm lymphedema reported by the Brazilian
studies ranged from 17.5 to 23.2% [20, 24]. The pooled
incidence was 21% (95% CI 15.0–26.0, I2 = 95.29%,
n = 11 studies) with considerable heterogeneity, while
that reported by circumferential measurement was 16%
(95% CI 9.0–23.0, I2 = 96.54%, n = 6 studies) (refer to
Fig. 4). The estimated pooled incidence by all other
methods of assessment was between 16.0% (circumferen-
tial measurement) and 26.0% (self-report).
Risk factors of lymphedema following breast cancer
treatment Ten of the 11 studies reporting on lymph-
edema risk factors, focused on the risk of developing
arm lymphedema following breast cancer treatment [21,
Fig. 2 Forest plot of pooled prevalence of arm and leg lymphedema
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27–30, 34, 41, 42, 45, 47]. One study [28] reported that
individuals with body mass index (BMI) of ≥30 were
6.64 times more likely to develop arm lymphedema than
those with BMI ≤17.9. The risk of developing arm
lymphedema among breast cancer women with BMI ≥25
ranges from the odds ratio (OR) of 1.5 to 5.9 compared
to participants with BMI < 25 [27, 28, 30, 42, 47]. We
obtained a pooled effect estimate OR of 1.98, 95% confi-
dence interval (CI): 1.45 to 2.70 (P < 0.0001; I2 = 84.0%)
in a random effect meta-analysis (refer to Fig. 5).
Axillary radiotherapy treatment is a significant risk
with an OR ranging from 2.7 to 4.4 [21, 27, 29]. Four
studies examined the risk of developing arm lymph-
edema associated with higher number of lymph node re-
moval among breast cancer survivors [21, 27, 42, 47].
The removal of lymph nodes of > 25 during mastectomy
was associated with a risk of developing arm lymph-
edema [4.88 (OR2.25–10.58)] among breast cancer
woman compared with when less number of lymph
nodes were removed [21]. Higher nodal ratio [1.135
(Hazard ratio (HR) 1.037–1.243)] was also found to be
associated with higher risk of arm lymphedema [42].
Lumpectomy was not a significant risk factor for arm
lymphedema [27].
Modified radical mastectomy was associated with an
OR of 4.3 (95% CIs: 2.3–7.9) risk than those who did not
and participants who received radiotherapy had an OR
of 3.9 (95% CIs: 1.8–8.2) risk of developing arm lymph-
edema compared with those who did not [47]. The
length of time after surgery for breast cancer was also
reported to be 9.7 times higher among breast cancer
women who had surgery more than 5 years as compared
to those with less years [34].
Other risk factors identified to significantly affect
lymphedema among breast cancer survivors include: past
history of limb damage had an OR of 1.7 (95% CIs: 0.9–
3.1) [47], presence of a co-morbid condition with a HR
of 0.1593 (95% CIs: 1.1441–2.9369) [45], post radiother-
apy moist desquamation had an OR of 4.34 (95% CIs:
1.07–17.65) [41], and presence of seroma after breast
cancer surgery [34]. Women with breast cancer tumour
invasion were 13.7 times at risk of developing arm
Fig. 3 Forest plot of pooled prevalence of cancer related lymphedema based on country of study publication
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lymphedema compared to those women who did not re-
ceive tumour invasion [47]. Cancer stage was not signifi-
cant in arm lymphedema following breast cancer
treatment [34, 41] (refer to Table 3).
Leg lymphedema following gynecological cancer treatment
All five studies that reported leg lymphedema used ei-
ther patient self-report (n = 3) or palpation or clinical
diagnosis (n = 2). Studies which used the self-report
method of lymphedema diagnosis only used either pal-
pation or observation methods of identifying lymph-
edema in the affected limbs of the patients [22, 50, 53].
These were based on patients’ reports of swelling in the
legs alone. In the case of the clinical diagnosis, lymph-
edema was identified as present when a positive Stem-
mer’s sign was recorded [40].
Prevalence of leg lymphedema following gynecological
cancer treatment Of the five studies reporting on leg
lymphedema, three focused on the prevalence of leg
lymphedema secondary to cervical cancer treatment; two
West African and one Romanian [22, 40, 50]. The preva-
lence estimates were similar; 7.0% (95% CI 3–15) [22],
11.0% (95% CI 8–15) [50] and 13% (95% CI 7–23) [40].
The three studies [22, 40, 50] that reported on leg
lymphedema following cervical cancer reported a pooled
prevalence of 10% (95% CI 7–13) with considerable het-
erogeneity. The method of measurement of lymphedema
was self-report and none of these studies explored leg
lymphedema risk factors.
Two studies reported leg lymphedema prevalence
based on clinical diagnosis among women who received
vulvectomy [49, 53]. The prevalence varied widely from
60.1% in the Brazilian study to 9.1% in the Nigerian
study [53].
The incidence of leg lymphedema was reported in only
one study, which focused on patients following inguinal
and ilioinguinal lymphadenectomies in Brazil and identi-
fied an incidence of 59.1% [20].
Risk factors of lymphedema following vulvar cancer
treatment One study reported the risk of developing leg
lymphedema following vulvar cancer treatment [49]. The
risk of leg lymphedema following vulvar cancer included
age associated with an OR of 1.09 (95% CIs: 1.00–1.18)
and a BMI with an OR of 1.34 (1.01–1.77) [49] (refer to
Table 3).
Sub-group analyses Planned sub-group analyses failed
to significantly reduce heterogeneity. Heterogeneity
Fig. 4 Forest plot of pooled lymphedema incidence according to arm lymphedema measurement methods
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based on: country of study publication and the type of
cancer was 95.29%; study region was 93.85%; sample
size, the type of measurement of lymphedema, and the
design of the study were 94.69%. The level of heterogen-
eity was 97.2% (n = 5 studies) for incidence and 94.89%
(n = 6 studies) for prevalence when focusing on low risk
of bias studies (refer to Table 4).
A post-hoc subgroup analysis was also conducted in
which we removed from the meta-analyses all studies
that had less than 24 months follow up (n = 5). This too
resulted in minimal improvement in heterogeneity.
Discussion
This systematic review and meta-analysis is the first to
attempt to estimate prevalence and incidence of lymph-
edema in LMICs. Arm lymphedema results were too
heterogeneous to reliably estimate prevalence or inci-
dence. Two studies suggest that the prevalence of leg
lymphedema may be between 7 and 13% [22, 50], while
only one study estimated incidence of leg lymphedema,
estimating it to be 59.1%, focusing specifically on
Brazilian patients following ilioinguinal lymphadenec-
tomy [20].
Differences in study quality, sample size estimations,
technique of sampling and study methodology typically
form the bases for heterogeneity in meta-analysis of
prevalence or incidence data, and this review is likely to
be no exception. Lymphedema following cancer treat-
ment might be influenced by lymphatic drainage, adju-
vant radiation therapy, hormonal therapy, skin care,
physiotherapeutic modalities such as simple home exer-
cises, and self-lymphatic drainage techniques [55] and
trastuzumab therapy and taxane-based chemotherapy
[56], but none of these variables were reliably reported.
Risk factors for arm lymphedema following breast cancer
treatment identified by this review did not differ from
those identified by studies in HICs [6, 57, 58]. BMI ≥25,
age above 60 years, having axillary radiotherapy treat-
ment with axillary lymph node dissection, ≥16 lymph
nodes removed, higher lymph node ratio, and increased
engagement in moderate to severe physical activity were
identified as the most significant risk factors of arm
lymphedema. The number of lymph nodes typically re-
moved in LMICs may be more compared to HICs be-
cause of later detection of cancer and differences in t the
type of treatment provided as standard. Such differences
in treatments and health management practices in
LMICs are likely to have accounted for at least some of
the variation found between the current review and that
conducted in HICs [59]. Lymphedema incidence and
Fig. 5 Effect of BMI on risk of arm lymphedema: adjusted effect measure and 95% confidence interval (CI) by study
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prevalence were generally higher in our review com-
pared to the previous review of studies conducted in
HICs [6]. However, comparability between these reviews
is limited by the heterogeneity among estimates and
general low quality of studies in LMICs [6]. However,
comparability between these reviews is limited by the
Table 3 Risk factors of lymphedema




Number of metastatic LNs
Having a Breast/Chest-wall RT
Having Axillary RT
Lumpectomya






Patients undergoing Level III Mastectomy/
Lumpectomy/ Chemotherapy/ Radiotherapy
Arm circumference measurement
Having mastectomy (ALND) +
RT
(Ozcinar, Guler et al. 2012) [29] Patients with ALND + RT had statistically
increased rate
of lymphedema than patients with ALND
and without RT
(p = 0.030)




Stage of the cancer (I-III)









Adjuvant RT + LND
Chemotherapy










(Paiva, Rodrigues et al. 2013) [34] 2.71(PR1.49–4.91)
1.15(PR0.78–2.92)a
Surgery for > 5 years is 9.7 times higher
frequency than < 5 years
Women undergoing oncology follow up
Perimetry
Staging (Locally advanced III)a
Post RT skin necrosis
(Khanna, Gupta et al. 2019) [41] 2.21(OR 0.54–9.04)a
4.34 (OR1.07–17.65)
Early and locally advanced stages
Arm circumference measurement
Higher BMI
Increasing number of lymph
nodes dissected
Higher nodal ratio
Regional Lymph Node Radiation
(RLNR)













Engaging in moderate to severe
physical activity
BMI of ≥25
Invasiveness of the tumor
Modified Radical Mastectomy
Having radiotherapy
Past history of limb damage
Number of lymph nodes
removed







Women with breast cancer
Arm circumference measurement
BMI (Ay, Kutun et al. 2014) [28] BMI of 25–29.9 was 1.445 times
more likely to develop lymphoedema than
a patient with a BMI
of < 17.9 (p < 0.001), and a patient with a
BMI of 30–34.9 was
6.643 times more likely to develop it than
a patient with a BMI of
< 17.9 (p < 0.001).






(de Melo Ferreira, de Figueiredo






aNot significant in the final model
RT Radiotherapy, LN Lymph node, BMI Body mass index; Lymph node dissection
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heterogeneity among estimates and general low quality
of studies in LMICs..
While several different methods are available for meas-
uring lymphedema, the majority of studies included in
this review used the circumferential measurements and
patients’ self-reports. Circumferential measurement is a
non-invasive, inexpensive and practical method of
lymphedema measurement in the clinical setting [6, 60]
with established reliability [61]. Self-report, on the other
hand, is open to subjective variability between patients
and is typically used in the clinic to assess the patient’s
view of improvement [6, 60] and likely to report higher
rates compared with the more objective lymphedema
measurement methods like circumferential measure-
ments [62]. One study [26] reported on the use of
bioimpedance spectroscopy in diagnosing lymphedema.
Although this method has demonstrated high sensitivity
and specificity, the equipment is expensive and few
health facilities even in HICs are able to afford it [63],
prohibiting its use in LMICs.
Limitations
The limitations of this study arise from the limited num-
ber of available studies and incomplete reporting, espe-
cially with regard to disease stage and treatment. Studies
were limited to a small range of countries in certain geo-
graphical regions. None of the studies controlled for pre-
morbid lymphedema.
Implications for future research
Notable gaps that should be filled by future research in-
clude studies of the prevalence of lymphedema in certain
geographical regions, such as Africa. Because affected
people may sometimes resort to traditional and other
alternative treatment rather than hospitals in the first in-
stance [64], community-based research may be neces-
sary. In the absence of a gold standard lymphoedema
measurement, reaching global consensus on the most re-
liable and feasible method of identifying lymphedema in
LMICs would do much to enable comparability between
studies, and to assess the impact of any treatments. Un-
derstanding the impact the role of social-determinates of
health and culture have on lymphedema prevalence and
incidence rates in LMICs are important areas for future
research.
Lymph node sparring is considered an invaluable sur-
gical method for lymphedema prevention [65]. However,
due to the quality of reporting we were unable to exam-
ine its impact on lymphedema prevalence or incidence
in LMICs.
Conclusion
This systematic review and meta-analysis was unable to
reliably estimate the prevalence or incidence of lymph-
edema in LMICs due to heterogeneity (arm lymph-
edema) and small numbers of studies (leg lymphedema).
Heterogeneity among estimates is likely due to differ-
ences in measurement methods, as well as variability in
stage of cancer, treatments and other variables not reli-
ably reported. Rates were higher according to self-report
or compared with more objective measures, such as the
clinical diagnosis or the circumferential measurements.
Gaining consensus on how best to measure lymphedema
in LMICs would enable comparability between studies
and more reliable estimates. Better understanding the
factors contributing to the wide variability in arm
lymphedema is an important first step to developing tar-
geted interventions to improve the quality of life of
people living with cancer related lymphedema in LMICs.
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